RU2014153760A - Водные гелеобразующие композиции растворимых активных фармацевтических пептидов, обеспечивающие модифицированное высвобождение - Google Patents

Водные гелеобразующие композиции растворимых активных фармацевтических пептидов, обеспечивающие модифицированное высвобождение Download PDF

Info

Publication number
RU2014153760A
RU2014153760A RU2014153760A RU2014153760A RU2014153760A RU 2014153760 A RU2014153760 A RU 2014153760A RU 2014153760 A RU2014153760 A RU 2014153760A RU 2014153760 A RU2014153760 A RU 2014153760A RU 2014153760 A RU2014153760 A RU 2014153760A
Authority
RU
Russia
Prior art keywords
composition
peptide
composition according
paragraphs
concentration
Prior art date
Application number
RU2014153760A
Other languages
English (en)
Russian (ru)
Inventor
Мари-Мадлен БАРОННЕ
Жоэль Ришар
Натали Мондоли
Дидье Нурриссон
Original Assignee
Ипсен Фарма С.А.С.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ипсен Фарма С.А.С. filed Critical Ипсен Фарма С.А.С.
Publication of RU2014153760A publication Critical patent/RU2014153760A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68Melanocyte-stimulating hormone [MSH]
    • C07K14/685Alpha-melanotropin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
RU2014153760A 2012-06-08 2013-06-06 Водные гелеобразующие композиции растворимых активных фармацевтических пептидов, обеспечивающие модифицированное высвобождение RU2014153760A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12290189.5 2012-06-08
EP12290189.5A EP2705835A1 (en) 2012-06-08 2012-06-08 Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
PCT/EP2013/061732 WO2013182653A1 (en) 2012-06-08 2013-06-06 Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release

Publications (1)

Publication Number Publication Date
RU2014153760A true RU2014153760A (ru) 2016-08-10

Family

ID=48577065

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014153760A RU2014153760A (ru) 2012-06-08 2013-06-06 Водные гелеобразующие композиции растворимых активных фармацевтических пептидов, обеспечивающие модифицированное высвобождение

Country Status (7)

Country Link
US (2) US20150157719A1 (https=)
EP (2) EP2705835A1 (https=)
JP (1) JP2015518873A (https=)
CN (1) CN104487049A (https=)
HK (1) HK1208171A1 (https=)
RU (1) RU2014153760A (https=)
WO (1) WO2013182653A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3539551T (lt) 2011-12-29 2022-01-10 Rhythm Pharmaceuticals, Inc. Su melanokortino-4 receptoriumi susijusių sutrikimų gydymo būdas heterozigotiniuose nešiotojuose
CN115957297A (zh) 2013-03-15 2023-04-14 节奏制药公司 药物组合物
EP2970388B1 (en) 2013-03-15 2018-07-25 Rhythm Pharmaceuticals, Inc. Peptide compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331922B (en) * 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
NZ565217A (en) 2005-07-08 2010-03-26 Ipsen Pharma Sas Melanocortin receptor ligands
US20100098735A1 (en) * 2006-10-05 2010-04-22 Rajesh Jain Injectable depot compositions and its process of preparation
TWI364290B (en) 2007-05-25 2012-05-21 Ipsen Pharma Sas Melanocortin receptor ligands modifled with hydantoin
TW200916113A (en) * 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
WO2009151714A2 (en) * 2008-03-24 2009-12-17 Palatin Technologies, Inc. Therapeutic for treatment of circulatory shock, ischemia, inflammatory disease and related conditions
JP5486690B2 (ja) * 2009-11-16 2014-05-07 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ メラノコルチン受容体リガンドの医薬組成物
BR112013027222B1 (pt) * 2011-06-14 2022-07-12 Ipsen Pharma S.A.S. Composição de liberação sustentada que contém peptídeos como ingrediente ativo

Also Published As

Publication number Publication date
WO2013182653A1 (en) 2013-12-12
JP2015518873A (ja) 2015-07-06
HK1208171A1 (en) 2016-02-26
EP2858626A1 (en) 2015-04-15
US20150157719A1 (en) 2015-06-11
EP2705835A1 (en) 2014-03-12
US20170035884A1 (en) 2017-02-09
CN104487049A (zh) 2015-04-01

Similar Documents

Publication Publication Date Title
CO6680640A2 (es) Uso de aglutinantes para fabircar formulaciones estables al almacenamiento
WO2017044894A3 (en) Cartilage-homing peptides
NZ604026A (en) Injectable flowable composition comprising buprenorphine
RU2015137145A (ru) Новые жидкие композиции с повышенной стабильностью
BRPI0514297A (pt) composições farmacêuticas para liberação controlada de compostos biologicamente ativos
PE20141671A1 (es) Forma de dosis farmaceutica oral a prueba de manipulacion que comprende un agente antagonista y/o repelente opioide, oxido de polialquileno y un polimero anionico
PH12014502778A1 (en) Antibody formulation
MX2013001677A (es) Formulaciones estables de linaclotida.
MX354102B (es) Derivados de bencimidazol-prolina.
EA200970348A1 (ru) Новые инъецируемые депо-композиции и способ получения таких композиций
UA104945C2 (uk) Фармацевтична композиція лігандів рецепторів секретагогів гормону росту
WO2013006743A3 (en) Personal care compositions with improved solubility of a solid cosmetic active substance
RU2010149561A (ru) Твердое лекарственное средство с замедленным высвобождением действующих веществ
MY175309A (en) Pharmaceutical composition useful for adhesion prevention or hemostasis
MX2017013244A (es) Dentifricos a base de calcio para una mejor absorcion de los ingredientes activos.
JP2018154613A5 (https=)
RU2014153760A (ru) Водные гелеобразующие композиции растворимых активных фармацевтических пептидов, обеспечивающие модифицированное высвобождение
AR062979A1 (es) Formulaciones orales liofilizadas de desintegracion rapida de un antagonista del receptor de trombina
EA201490363A1 (ru) Новые составы на основе (триметоксифениламино)пиримидинилов
MX359713B (es) Composiciones mejoradas para la cicatrizacion de heridas que comprenden microesferas.
EA201300857A1 (ru) Пиразолы в качестве антагонистов crth2
WO2012172433A3 (en) A sustained -release composition containing a melanocortin receptor ligand as the active ingredient
JP2015518873A5 (https=)
PH12015502717A1 (en) Anti-fibrogenic compounds, methods and uses thereof
FI4000628T3 (fi) Koostumus ja menetelmä vankomysiinin oraaliselle nesteelle

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20170814